Various non-injectable delivery systems for the treatment of diabetes mellitus

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 1, 2009, Pages 9-13

  Yadav, Neha ^a   Morris, Gordon ^a   Harding, S E ^a   Ang, Shirley ^a   Adams, Gary G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Aerosols; Dry powder inhalers; Hydrogels; Insulin delivery; Microcapsules

Indexed keywords

EYE DROPS; INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN;

AEROSOL; ARTERIAL PRESSURE; CELL THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INSTILLATION; DRY POWDER; HUMAN; HYDROGEL; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MICROCAPSULE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE IRRITATION; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; POWDER INHALER; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; NEBULIZER;

AEROSOLS; CAPSULES; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGELS; INSULIN; NEBULIZERS AND VAPORIZERS;

EID: 65549166428     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009787582405     Document Type: Review

References (129)

1. http://www.who.int/diabetes/en/ last accessed on 2008-01-28.
2. Diabetes Atlas, 3rd ed. © International Diabetes Federation, 2006.
3. Williams, R.; Airey, M.; Baxter, H.; Forrester, J.; Kennedy-Martin, T. and Girach, A. (2004) Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye, 18(10), 963-983.
4. Tesch, G.H. and Nikolic-Paterson, D.J. (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Nephron. Exp. Nephrol., 104(2), e57-e62.
5. Evans, M.J. and M.H. Kaufman (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature, 292(5819), 154-156.
6. Somers, E.C.; Thomas, S.L.; Smeeth, L. and Hall, A.J. (2004) Autoimmune diseases co-occurring within individuals and within families: A systematic review. Epidemiology, 17(2), 202-217.
7. Steil, G.M.; Panteleon, A.E. and Rebrin, K. (2004) Closed-loop insulin delivery - the path to physiological glucose control. Adv. Drug Deliv. Rev., 56(2), 125-144.
8. Varshosaz, J. (2007) Insulin delivery systems for controlling diabetes. Recent Patents Endocrine, Metab. Immun. Drug Discov., 16(1), 25-40.
9. Silvaa, C.; Ribeirob, A.J.; Ferreirac, D. and Veigaa, F. (2006) Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation. Eur. J. Pharm. Sci., 29(2), 148-159.
10. Barichello, J.M.; Morishita, M.; Takayama, K.; Chiba, Y.; Tokiwa, S. and Nagai, T. (1999) Enhanced rectal absorption of insulin-loaded Pluronic® F-127 gels containing unsaturated fatty acids. Int. J. Pharm., 183(2), 125-132.
11. Owens, D.R.; Zinman, B. and Bolli, G. (2003) Alternative routes of insulin delivery. Diabet. Med., 20(11), 886-898.
12. Narayani, R. (2001) Artificial cell therapy: new strategies for the therapeutic delivery of live bacteria. Trends Biomater. Artifi. Organs, 15(1), 12-16.
13. Lee, Y.C.; Simamora, P. and Yalkowsky, S.H. (1997) Systemic delivery of insulin via an enhancer-free ocular device. J. Pharm. Sci., 86(12), 1361-1364.
14. Chiou, G.C.Y. (1991) Effect of formulation on the systemic absorption of insulin from enhancer-free ocular devices. Annu. Rev. Pharmacol., 31(1), 457-467.
15. Lee, Y.C.; Simamora, P. and Yalkowsky, S.H. (1997) Effect of Brij-78 on systemic delivery of insulin from an ocular device. J. Pharm. Sci., 86(4), 430-433.
16. Jabbal-Gill, I.; Fisher, A.N.; Rappuoli, R.; Davis, S.S. and Illum, L. (1998) Vaccination of rock bream, Oplegnathus fasciatus (Temminck & Schlegel), using a recombinant major capsid protein of fish iridovirus. Vaccine, 16(20), 2039-2046.
17. Cernea, S. and Raz, I. (2006) Intranasal insulin: PK profile designed specifically for prandial treatment of Type 2 Diabetes. Drugs Today, 42(6), 405-424.
18. Gizurarson, S. and Bechgaard, E. (1991) Intranasal administration of insulin to humans. Diabetes Res. Clin. Pract., 12(2), 71-84.
19. Turker, S.; Onur, E. and Ozer, Y. (2004) Pharmaceutical significance of chitosan: A review. Pharm. World Sci., 26(3), 137-142.
20. Drejer, K.; Vaag, A.; Bech, K.; Hansen, P.; Sorensen, A.R. and Mygind, N. (1992) Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. Diabet. Med., 9(4), 335-340.
21. Jacobs, M.A.; Schreuder, R.H.; Jap-A-Joe, K.; Nauta, J.J.; Andersen, P.M. and Heine, R.J. (1993) The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Diabetes, 42(11), 1649-1655.
22. Moses, A.C.; Gordon, G.S.; Carey, M.C. and Flier, J.S. (1983) Nasal absorption of insulin: enhancement by hydrophobic bile salts. Diabetes, 32(11), 1040-1047.
23. Nolte, M.S.; Taboga, C.; Salamon, E.; Moses, A.; Longenecker, J.; Flier, J. and Karam, J.H. (1990) Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Hormone Metab. Res., 22(3), 170-174.
24. Bruce, D.G.; Chisholm, D.J.; Storlien, L.H.; Borkman, M. and Kraegen, E.W. (1991) Meal-time intranasal insulin delivery in Type 2 diabetes. Diabet. Med., 8(4), 366-370.
25. Liu, L.; Fishman, M.L. and Hicks, K.B. (2007) Pectin in controlled drug delivery - a review. Cellulose, 14(1), 15-24.
26. Liu, L.; Fishman, M.L.; Kost, J. and Hicks, K.B. (2003) Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials, 24(19), 3333-3343.
27. Cernea, S.; Kidron, M.; Wohlgelernter, J.; Modi, P. and Raz, I. (2004) Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycaemic clamp technique. Clin. Ther., 26(12), 2084-2091.
28. Modi, P.; Mihic, M. and Lewin, A. (2002) The evolving role of oral insulin in the treatment of diabetes using a novel RapidMistSystem. Diab. Metab. Res. Rev., 18(1), S38-S42.
29. Lin, Y.H.; Chen, C.H.; Liang, H.F.; Kulkarni, A.R.; Lee, P.W.; Chen, C.H. and Sung, H.W. (2007) Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology, 18(10), 1-11.
30. Carino, G.P.; Jacob, J.S. and Mathiowitz, E. (2000) Nanosphere based oral insulin delivery. J. Control. Rel., 65(1-2), 261-269.
31. Mesiha, M.; Plakogiannis, F. and Vejosoth, S. (1994) Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: Ex vivo and in vivo studies. Int. J. Pharm., 111(3), 213-216.
32. Yamamoto, A.; Taniguchi, T.; Rikyuu, K.; Tsuji, T.; Fujita, T.; Murakami, M. and Muranishi, S. (1994) Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res., 11(10), 1496-1500.
33. Morishita, I.; Morishita, M.; Takayama, K.; Machida, Y. and Nagai, T. (1993) Enteral insulin delivery by microspheres in 3 different formulations using Eudragit® L100 and S100. Int. J. Pharm., 91(1), 29-37.
34. Sarmento, B.; Ribeiro, A.; Veiga, F.; Ferreira, D. and Neufeld, R. (2007) Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules, 8(10), 3054-3060.
35. Jain, D.; Panda, A.K. and Majumdar, D.K. (2005) Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS Pharm. Sci. Tech., 6(1), E100-E107.
36. Gaensslen, M. (1925) Ueber Inhalation von Insulin. Klin. Wochenschr, 4(2), 71.
37. Banting, F.G.; Best, C.H. and Macleod, J.J.R. (1922) The internal secretion of the pancreas. Am. J. Physiol., 59(1), 479.
38. Cernea, S.; Kidron, M.; Wohlgelernter, J.; Modi, P. and Raz, I. (2005) Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care, 28(6), 1353-1357.
39. Mygind, N. (1985) Treating Diabetes With Aerosolized Insulin: in Aerosols in medicine. Principles, diagnosis and therapy (Moren, F.; Newhouse, M.T. and Dolovich, M. B. Eds.), New York, Elsevier Science Publishers, 1-20.
40. Byron, P.R. (1986) Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci., 75(5), 433-438.
41. Gil, J. (1983) Number and distribution of plasmalemmal vesicles in the lung. Fed. Proc., 42(8), 2414-2418.
42. Jendle, J.H. and Karlberg, B.E. (1996) Intrapulmonary insulin administration in healthy volunteers. J. Int. Med., 240(2), 93-98.
43. Galloway, J.A.; Spradlin, C.T.; Nelson, R.L.; Wnetworth, S.M.; Davidson, J.A. and Swarner, J.L. (1981) Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care, 4(3), 366-376.
44. Patton, J. (2006) Pulmonary delivery of insulin. Curr. Med. Res. Opin., 22(3), S5-S11.
45. Scheuch, G. and Siekmeier, R. (2007) Novel approaches to enhance pulmonary delivery of proteins and peptides. J. Physiol. Pharmacol., 58(5), 615-625.
46. Agu, R.U.; Ugwoke, M.I.; Armand, M.; Kinget, R. and Verbeke, N. (2001) The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res., 2(4), 198-209.
47. Niven, R.W. (1995) Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst., 12(2-3), 151-231.
48. Deshpande, D.; Blanchard, J.; Srinivasan, S.; Fairbanks, D.; Fujimoto, J.; Sawa, T.; Wiener-Kronish, J.; Schreier, H. and Gonda, I. (2002) Aerosolization of lipoplexes using AERx® pulmonary delivery system. AAPS Pharm. Sci., 4(3), 1-10.
49. Mandal, T.K. (2005) Inhaled insulin for diabetes mellitus. Am. J. Health-Syst. Pharm., 62(13), 1359-1364.
50. Laube, B.L. (2001) Treating diabetes with aerosolised insulin. Chest, 120(3), 99S-106.
51. Crowder, T.M.; Louey, M.D.; Sethuraman, V.V; Smyth, H.D.C. and Hickey, A. (2001) An odyssey in inhaler formulations and design. J. Pharm. Tech., 25(7) 99-113.
52. Laube, B.L.; Benedict, W. and Dobs, A.S. (1998) Time to peak insulin level, relative bioavailability and effect of site of deposition of nebulized insulin in patients with non-insulin-dependent diabetes mellitus. J. Aerosol. Med., 11(3), 153-173.
53. Elliott, R.B.; Edgar, B.W.; Pilcher, C.C.; Quested, C. and McMaster, J. (1987) Aust. Paediatr. J., 23(5), 293-297.
54. Selam, J.L. (2003) Inhaled insulin for the treatment of diabetes: projects and devices. Exp. Opin. Pharmacol., 4(8), 1373-1377.
55. Mumenthaler, M.; Hsu, C.C. and Pearlman, R. (1994) Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. Pharm. Res., 11(1), 12-20.
56. Heinemann, L.; Pfutzner, A. and Heise, T. (2001) Alternative routes of administration as an approach to improve insulin therapy: Update on dermal, oral, nasal and pulmonary insulin delivery. Curr. Pharm. Des., 7(14), 1327-1351.
57. Schultz, H. (1998) Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies. Pharmaceut. Sci. Technol., 1(8), 336-344.
58. Farr, S.J.; McElduff, A.; Mather, L.E.; Okikawa, J.; Ward, M.E.; Gonda, I.;Vojtech, L. and Rubsamen, R.M. (2000) Pulmonary insulin administrationusing the AERx™ system: physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Therapeut., 2(2)185-197.
59. Brådvik, I.; Wollmer, P.; Evander, E.; Sloth, M.; Lárusdóttir, H.; Blom-Bülow, B. and Jonson, B. (2000) One year follow-up of lung clearance of 99mTc-diethylene traimine penta-acetic acid and diseases activity in sarcodisis. Vasculitis Diffuse Lung Dis., 17(3), 281-287.
60. Wollmer, P. and Evander, E. (1994) Biphasic pulmonary clearance of 99mTc-DPTA in smokers. Clin. Physiol., 14(5), 547-559.
61. Minty, B.D.; Royston, D.; Jones, J.G. and Hulands, G.H. (1984) The effect of nicotine on pulmonary epithelial permeability in man. Chest, 86(1), 72-74.
62. Meignan, M.; Rosso, J.; Leveau, J.; Katz, A.; Cinotti, L.; Madelaine, G. and Galle, P. (1986) Exercise increases the lung clearance of inhaled technetium-99m DPTA. J. Nucl. Med., 27(2), 274-280.
63. Schmekel, B.; Borgstrom, L. and Wollmer, P. (1992) Exercise increases the rate of pulmonary absorption of inhaled terbulatie. Chest, 101(3), 742-745.
64. Fink, J.B. (2000) Metered-dose inhalers, dry powder inhalers, and transitions. Resp. Care, 456(6), 623-635.
65. Kubelka, J.; Huang, R. and Keiderling, T.A. (2005) Solvent effects on ir and vcd spectra of helical peptides: dft-based static spectral simulations with explicit water. J. Phys. Chem. B., 109(16), 8231-8243.
66. Laube, B.L.; Georgopoulos, A. and Adams 3rd, G.K. (1993) Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA, 69(16), 2106-2109.
67. Maa, Y.F. and Prestrelski, S.J. (2000) Biopharmaceutical powders particle formation and formulation considerations. Curr. Pharm. Biotech., 1(3), 283-302.
68. Tyagi, P. (2002) Insulin delivery systems: present trends and the future direction. Ind. J. Pharmacol., 34(6), 379-389.
69. Thompson, P.J. (1998) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 157(5), 199-202.
70. Keller, M. and Müller-Walz, R. (2000) Development of dry powder inhalers WO0028979.
71. Chougule, M.B.; Padhi, B.K.; Jinturkar, K.A. and Misra, A. (2007) Development of dry powder inhalers. Recent Patents Drug Deliv. Formulat., 1(1), 11-21.
72. Edwards, D.A.; Ben-Jerbria, A. and Langer, R. (1998) Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol., 85(2), 379-385.
73. Rosenstock, J. (2002) Mealtime rapid acting inhaled insulin (Exubera®) improves glycaemic control in patients with type 2 diabetes failing combination oral agents: a 3 month randomised comparative trial. Diabetes, 51(2), A132-A133.
74. Belanger, A. (2002) Efficacy and safety of inhaled insulin (Exubera®) compared to sc insulin therapy in patients with type 2 diabetes. Results of a 6 month randomised comparative trial. Diabetologia, 45(2), A260.
75. Henry, R.R.; Mudaliar, S.R.; Howland, W.C.III; Chu, N.; Kim, D.; An, B. and Reinhardt, R.R. (2003) Pulmonary delivery of insulin using the AERx™ insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care, 26(3), 764-769.
76. Skyler, J.S.; Weinstock, R.S.; Raskin, P.; Yale, J.F.; Barrett, E.; Gerich, J. E. and Gerstein, H.C. (2005) Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects A 6-month, randomized, comparative trial. Diabetes Care, 28(7), 1630-1635.
77. DeFronzo, R.A.; Bergenstal, R.M.; Cefalu, W.T.; Pullman, J.; Lerman, S.; Bode, B.W. and Phillips, L.S. (2005) Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care, 28(8), 1922-1928.
78. Weiss, S.R.; Cheng, S.L.; Kourides, I.A.; Gelfand, R.A.; Landschulz, W.H. (2003) The Inhaled Insulin Phase II Study Group: Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch. Intern. Med., 163(19), 2277-2282.
79. Cefalu, W.T.; Balagtas, C.C.; Landshultz, W. H. and Gelfand, R.A. (2000) Sustained efficacy and pulmonary safety of inhaled insulin during 2 years of outpatient therapy. Diabetologia, 43(1), A47.
80. Staniforth, J.N. (1995) Development of dry powder inhalers WO9511666.
81. Trofast, J. (1998) New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising Formoterol WO9831351.
82. Edwards, D.A.; Caponetti, G.H.; Jeffrey, S.; Lotan, N.; Hanes, J.; Ben-Jebria, A. and Langer, R.S. (2000) Development of dry powder inhalers US20006399102.
83. Edwards, D.A.; Caponetti, G.H.; Jeffrey, S.; Lotan, N.; Hanes, J.; Ben-Jebria, A. and Langer, R.S. (2005) Development of dry powder inhalers US20050244341.
84. Hodson, P.D.; Smith, D.K.; Velasquez, D.J.; Wass, A.C.L. and Calhoun, C.D. (1998) Development of dry powder inhalers US5740793.
85. Jahr, H. and Bretzel, B. (2003) Insulin-positive cells in vitro generated from rat bone marrow stromal cells. Transplant. Proc., 35(6), 2140-2141.
86. Ianus, A.; Holz, G.G.; Theise, N.D. and Hussain, M.A. (2003) In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J. Clin. Invest., 111(6), 843-850.
87. Newgard, C.B. (2005) An artificial beta cell produced by engineering endocrine cells of the At-T-20 ACTH secreting cells. US5427940.
88. Laurance, M.E.; Knaack, D.; Fiore, D.M. and Hegre, O.D. (1996) Glucose responsive insulin secreting beta-cell lines. US5534404.
89. Stock, P.G. and Bluestone, J.A. (2004) Beta-cell replacement for type I diabetes. Ann. Rev. Med., 55(1), 133-156.
90. Tanaka, T.; Fillmore, D.; Sun, S.; Nishio, I.; Swislow, G. and Shah, A. (1980) Phase transitions in ionic gels. Phys. Rev. Lett., 45(20), 1636-1639.
91. Hoffman, J.; Plotner, M.; Kuckling, D. and Fischer, W. (1999) Photopatterning of thermally sensitive hydrogels useful for micro-actuators. Sens. Actuators A. Phys., 77(2), 139-144.
92. Suzuki, A. and Tanaka, T. (1990) Phase transition in polymer gels induced by visible light. Nature, 346(6282), 345-347.
93. Kataoka, K.; Miyazaki, H.; Bunya, M.; Okano, T. and Sakurai, Y. (1998) Totally synthetic polymer gels responding to external glucose concentration: Their preparation and application to on-off regulation of insulin release. J. Am. Chem. Soc., 120(48), 12694-12695.
94. Miyata, T.; Asami, N. and Uragami, T. (1999) A reversibly antigen-responsive hydrogel. Nature, 399(6738), 766-796.
95. Tanaka, T.; Nishio, I.; Sun, S. and Nishio, S. (1982) Collapse of gels in an electric field. Science, 218(4571), 467-469.
96. Kato, N.; Takahashi, F. and Yamanobe, S. (1997) Property of magneto-driven poly (N-isopropylacrylamide) gel containing iron oxide in NaCl solution as a chemomechanical device. Mater. Sci. Eng. C, Biol., 5(2), 141-147.
97. Nagarsekar, A.; Crissman, J.; Crissman, M.; Ferrari, F.; Cappello, J. and Ghandehari, H. (2002) Genetic synthesis and characterization of pH- and temperature-sensitive silk-elastinlike protein block copolymers. J. Biomed. Mater. Res., 62(2), 195-203.
98. Harland, R.S. (1992) Polyelectrolyte Gels: Properties, Preparation and Applications In: Polyelectrolyte gels: Properties, Preparation, and Application (Prud Homme R. K. Eds.), American Chemical Society, Washington D. C., pp. 285.
99. Park, T.G. (1999) Temperature modulated protein release from pH/ temperature-sensitive hydrogels. Biomaterials, 20(6), 517- 521.
100. Gehrke, S.H.; Uhden, L.H. and McBride, J.F. (1998) Enhanced loading and activity retention of bioactive proteins in hydrogel delivery systems. J. Control. Rel., 55(1), 21-33.
101. Chang, T.M.S. (1964) Ultrathin polymer membrane microcapsules for the immunoprotection of transplanted cells. Science, 146(3642), 524-525.
102. Lim, F. and Sun, A.M. (1980) Microencapsulated islets as bioartificial endocrine pancreas. Science, 210(4472), 908-909.
103. Sun, A.M.F.; Goosen, M.F.A. and O'Shea, G. (1987) Transdermal modulated delivery of polypeptides. CRC Crit. Rev. Ther. Drug Carrier Syst., 4(1), 1-12.
104. Sullivan, S.J.; Maki, T.; Borland, K.M.; Mahoney, M.D.; Solomon, B.A.; Muller, T.E.; Monaco A.P. and Chick, W.L. (1991) Biohybrid artificial pancreas: long-term implantation studies in diabetic, pancreatectomized dogs. Science, 252(5006), 718-721.
105. Sun, Y.L.; Ma, X.J.; Zhou, D.B.; Vacek, I. and Sun, A.M. (1996) Normalization of diabetes in spontaneously diabetic cynomologous monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J. Clin. Invest., 98(6), 1417-1422.
106. Hortelano, G.; Al-Hendy, A.; Ofosu, F.A. and Chang, P.L. (1996) Delivery of human Factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia. Blood, 87(12), 5095-5103.
107. Xu, W.; Liu, L. and Charles, I.G. (2002) Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J., 16(2), 213-215.
108. Prakash, S. and Chang, T.M.S. (1996) Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat. Med., 2(8), 883-887.
109. Duff, R.G. (1985) Method of making a porous matrix particle. TIBTECH, 3(7), 167-170.
110. Fan, M.Y.; Lum, Z.P.; Fu, X.W.; Levesque, L.; Tai, I.T. and Sun, A.M. (1990) Reversal of diabetes in BB rats by transplantation of encapsulated pancreatic islets. Diabetes, 39(4), 519-522.
111. Serp, D.; Cantana, E.; Heinzen, C.; von Stockar, U. and Marison, I.W. (2000) Characterization of an encapsulation device for the production of monodisperse alginate beads for cell immobilization. Biotech. Bioeng., 70(1), 41-53.
112. Dias, J.C.T.; Rezende, R.P. and Linardi V.R. (2000) Biodegradation of acetonitrile by cells of Candida guilliermondii UFMG-Y65 immobilized in alginate, kappa-carrageenan and citric pectin. Braz. J. Microb., 31(1), 61-66.
113. Di'az-Rojasa, E.I.; Pacheco-Aguilara, R.; Lizardia, J.;
114. Argu"elles-Monalb, W.; Valdezc, M.A.; Rinaudod, M. and Goycooleaa, F.M (2004) Linseed pectin: gelling properties and performance as an encapsulation matrix for shark liver oil. Food Hydrocolloids, 18(2), 293-304.
115. Mao, S.; Bakowsky, U.; Jintapattanakit, A. and Kissel T. (2006) Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J. Pham. Sci., 95(5), 1035-1048.
116. Jederstrom, G.; Andersson, A.; Gråsjö, J. and Sjöholm, I. (2004) Blood glucose-lowering activity of a hyaluronan - insulin complex after oral administration to rats with diabetes. Pharm. Res., 21(11), 2040-2047.
117. Wee, S. and Gombotz, W.R. (1998) Protein release from alginate matrices. Adv. Drug Deliv. Rev., 31(3), 267-285.
118. Martinsen, A.; Skjak-Braek,G.; Smidsrod, O.; Zanetti, F. and Paoletti, S. (1991) Comparison of different methods for determination of molecular weight and molecular weight distribution of alginates. Carbohydr. Polym., 15(2), 171-193.
119. Smidsrod, O. and Skjak-Braek, G. (1990) Alginate as immobilization matrix for cells. TIBTECH, 8(3), 71-78.
120. 1 by the addition of polyacrylic acid within acid-treated beads. J. Control. Rel., 30(3), 241-251.
121. Ku, C.; Dixit, V.; Shaw, W. and Gitnick, G. (1995) In vitro slow release profile of endothelial cell growth factor immobilized within calcium alginate microbeads. Artif. Cells Blood Subs. Immob. Biotech., 23(2), 143-151.
122. Wan, L.S.; Heng, P.W. and Chan, L.W. (1992) Drug encapsulation in alginate microspheres by emulsification. J. Microencapsul., 9(3), 309-316.
123. Maysinger, D.; Jalsenjak, I. and Cuello, A.C. (1992) Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions. Neurosci. Lett., 140(1), 71-74.
124. Alexakis, T.; Boadi, D.; Quong, D.; Groboillot, A.; O'Neill, I.; Poncelet, D. and Neufeld, R. (1995) Microencapsulation of DNA within alginate microspheres and cross-linked chitosan membranes for in vivo application. Appl. Biochem. Biotech., 50(1), 93-106.
125. Monshipouri, M. and Price, R.R. (1995) Emulsification preparation of calcium alginate beads in the presence of sequesterant. J. Microencapsul., 12(3) 255-262.
126. Bungenberg de, J.M.G. (1949) in Colloid Science, (Kruyt, G. R. Ed.), Elsevier, New York, Vol. II, pp. 335-432.
127. Strand, B.L.; Ryan, T.L.; In't Veld, P.; Kulseng, B.; Rokstad, A.M.; Skjak-Brek, G. and Espevik, T. (2001) Poly-L-lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant., 10(3), 263-275.
128. Shapiro, A.M.J.; Lakey, J.R.T.; Ryan, E.A.; Korbutt, G.S; Toth, E.; Warnock, G.L.; Kneteman, N.M. and Rajotte, R.V. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med., 343(4), 230-238.
129. Orive, G.; Hernández, R.M.; Gascón, A.R.; Calafiore, R.; Chang, T.M. S.; De Vos, P.; Hortelano, G.; Hunkeler, D.; Lacík, I.; Shapiro A.M.J. and Pedraz, J.L. (2003) Cell encapsulation: Promise and progress. Nat. Med., 9(1), 104-107.